Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Clinical Oncology

• Publication date

  2005-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2005.04.120PMID 16009955
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The ne w e ngl and j our na l of medicine

  2006cited by this paper
• Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor

  2004cited by this paper
• Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen.

  2004cited by this paper
• A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.

  2004cited by this paper
• A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer*

  2004cited by this paper
• Tamoxifen for Prevention of Breast Cancer

  2003cited by this paper
• New approaches to the understanding of tamoxifen action and resistance.

  2003cited by this paper
• Aromatase inhibitors in breast cancer.

  2003cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses

  2003cited by this paper
• Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer.

  2003cited by this paper
• The role of aromatase inhibitors in the treatment of metastatic breast cancer.

  2003cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.

  2003cited by this paper
• Aromatase inhibitors in early breast cancer treatment.

  2003cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer

  2003cited by this paper
• Aromatase inhibitor development and hormone therapy: a perspective.

  2003cited by this paper
• Anastozole (A) is superior to tamoxifen (T) in treatment of postmenopausal (PM) women with early breast cancer (EBC) - First results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial (on behalf of the ATAC Trialists' Group)

  2002cited by this paper
• First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.

  2002cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

  2002cited by this paper
• Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.

  2002cited by this paper
• An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane

  2002cited by this paper
• Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study.

  2001cited by this paper
• Cellular and molecular pharmacology of antiestrogen action and resistance.

  2001cited by this paper
• National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.

  2001cited by this paper
• Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.

  2001cited by this paper
• Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.

  2001cited by this paper
• Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.

  2000cited by this paper
• Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.

  2000cited by this paper
• Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials

  1998cited by this paper
• Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

  1996cited by this paper
• Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group.

  1996cited by this paper
• Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.

  1996cited by this paper
• Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment.

  1994cited by this paper
• Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration.

  1988cited by this paper
• Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

  1977cited by this paper
• Regression Models and Life-Tables

  1972cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• Regression Models and Life-Tables

  year unknowncited by this paper
• A Meta-Analysis

  year unknowncited by this paper

• Patient-reported tolerance of 90 days of preoperative endocrine therapy: results from the preoperative window of endocrine therapy to inform radiation therapy decisions trial

  2025cites this paper
• The prevalence of menopausal level of follicle-stimulating hormone (FSH) in peri-menopausal breast cancer patients aged between 45 and 60 years

  2025cites this paper
• SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (UPDATE 2025)

  2025cites this paper
• Cardiotoxicity report of letrozole combined with pyrotinib as first-line treatment in HR+/HER2+ patients and new findings on lipid monitoring as predictive markers of efficacy: an analysis from the PLEHERM study

  2025cites this paper
• Triazole-Schiff Base Hybrids as Potential Dual Inhibitors of Bcl-2 and EGFR: Synthesis, Characterization, and Computational Insights.

  2025cites this paper
• Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole.

  2024cites this paper
• Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.

  2024cites this paper
• Osteoporotic fracture risk in women with breast cancer treated with aromatase inhibitors: a health insurance claims database study in Japan

  2024cites this paper
• Oral nano-formulations for endocrine therapy of endometrioid adenocarcinomas.

  2024cites this paper
• Risk of Cardiovascular Events and Lipid Profile Change in Patients with Breast Cancer Taking Aromatase Inhibitor: A Systematic Review and Meta-Analysis

  2023cites this paper
• Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care – The PreFace Study

  2023cites this paper
• Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care – The PreFace Study

  2023cites this paper
• Tamoxifen

  2023cites this paper
• SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)

  2023cites this paper
• Prevention of aromatase inhibitor–induced bone loss with anti-resorptive therapy in post-menopausal women with early-stage breast cancer

  2023cites this paper
• Hormone Treatment for Breast Cancer

  2023cites this paper
• Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting

  2023cites this paper
• Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis.

  2023cites this paper
• Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome.

  2023cites this paper
• Aromatase inhibitors: the journey from the state of the art to clinical open questions

  2023cites this paper
• Clinical Outcomes of Adjuvant Hormone Therapy in a Cohort of Patients With Infiltrating Non-metastatic Breast Cancer in a Latin American Cancer Center

  2022cites this paper
• Lipid Changes During Endocrine Therapy in Breast Cancer Patients: The Results of a 5-Year Real-World Retrospective Analysis

  2022cites this paper
• Hormonothérapie des cancers du sein en situations adjuvante, métastatique et néoadjuvante

  2022cites this paper
• Endocrine therapy initiation among women with stage I–III invasive, hormone receptor-positive breast cancer from 2001–2016

  2022cites this paper
• Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests

  2022cites this paper
• Prise en charge des cancers du sein infiltrants localisés : les nouveaux enjeux

  2021cites this paper
• Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis

  2021cites this paper
• Clinical and sociodemographic risk factors associated with the development of second primary cancers among postmenopausal breast cancer survivors

  2021cites this paper
• Tratamiento del cáncer de mama infiltrante localizado: nuevos desafíos

  2021cites this paper
• Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial.

  2021cites this paper
• Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial

  2020cites this paper
• Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer

  2020cites this paper
• Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial.

  2020cites this paper
• Effect of Traditional Chinese Medicine on Musculoskeletal Symptoms in Breast Cancer: A Systematic Review and Meta-Analysis.

  2020cites this paper
• Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies

  2020cites this paper
• Molecular mechanisms and clinical management of cancer bone metastasis

  2020cites this paper
• Osteoporotic Fractures of the Spine, Hip, and Other Locations after Adjuvant Endocrine Therapy with Aromatase Inhibitors in Breast Cancer Patients: a Meta-analysis

  2020cites this paper
• Hormone-Responsive Cancers

  2019cites this paper
• Adjuvant Systemic Therapy: Endocrine Therapy

  2019cites this paper
• Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis

  2019cites this paper
• Breast Cancer

  2019cites this paper
• Tamoxifen-induced hepatotoxicity via lipid accumulation and inflammation in zebrafish.

  2019cites this paper
• French Recommendations on Strategies for Preventing and Treating Osteoporosis Induced by Adjuvant Breast Cancer Therapies.

  2019cites this paper
• Adjuvant Systemic Therapy in Breast Cancer

  2019cites this paper
• Recommandations françaises de stratégies thérapeutiques pour la prévention et le traitement de l’ostéoporose induite par les traitements adjuvants du cancer du sein

  2019cites this paper
• Is Adjuvant Endocrine Therapy Indicated for DCIS Patients After Complete Surgical Excision?

  2018cites this paper
• Ageing perceptions and non-adherence to aromatase inhibitors among breast cancer survivors.

  2018cites this paper
• Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

  2018cites this paper
• Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.

  2018cites this paper
• Adjuvant Endocrine Therapy

  2018cites this paper
• Practical consensus recommendations on duration of adjuvant hormonal therapy in breast cancer

  2018cites this paper
• SEOM clinical guidelines in early stage breast cancer (2018)

  2018cites this paper
• Aging Perceptions and Non-Adherence to Aromatase Inhibitors among Breast Cancer Survivors

  2018cites this paper
• Adjuvant Endocrine Therapy

  2018cites this paper
• Adjuvant and neoadjuvant systemic therapies for early-stage breast cancer

  2018cites this paper
• Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysis

  2018cites this paper
• Effects of breast cancer hormone treatment on lipids and subsequent cardiovascular diseases

  2017cites this paper
• Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors

  2017cites this paper
• Low-trauma fractures without osteoporosis

  2017cites this paper
• Breast Cancer Survivors And Medication Adherence: The Role Of Health Beliefs, Perceptions Of Aging, And Partner Support

  2017cites this paper
• Dynamic strategy for personalized medicine: An application to metastatic breast cancer

  2017influential citation
• Updates on Adjuvant Therapy for Early Stage Hormone Receptor-Positive Breast Cancer

  2017cites this paper
• Aromatase Inhibitors for the adjuvant treatment of breast cancer in postmenopausal women

  2017cites this paper
• Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients

  2017cites this paper
• Tratamiento hormonal del cáncer de mama

  2017cites this paper
• Switching between endocrine therapies for primary breast cancer: Frequency and timing in Australian clinical practice

  2017cites this paper
• Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors

  2017cites this paper
• Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials

  2016cites this paper
• Adjuvant Therapy and Ovarian Function

  2016cites this paper
• InforMatrix Aromatase Inhibitors in Breastcancer

  2016cites this paper
• Influencia de la edad como factor pronóstico en la decisión terapéutica y de supervivencia en el cáncer de mama

  2016cites this paper
• Cancer of the Breast: An Overview

  2016cites this paper
• Update on breast cancer risk prediction and prevention

  2015cites this paper
• Adjuvant Aromatase Inhibitor Therapy in Early Breast Cancer: What Factors Lead Patients to Discontinue Treatment?

  2015cites this paper
• Update on Adjuvant Endocrine Therapy in Breast Cancer

  2015influential citation
• Perbedaan β-crosslaps Serum Penderita Karsinoma Payudara Pascamenopause antara yang Diberikan Anastrozol dan Tamoksifen

  2015cites this paper
• Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.

  2015cites this paper
• Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.

  2015cites this paper
• Development and validation of the Penn Arthralgia Aging Scale among breast cancer survivors

  2015cites this paper
• Association between self-report adherence measures and oestrogen suppression among breast cancer survivors on aromatase inhibitors.

  2015cites this paper
• The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy.

  2015cites this paper
• Aromatase inhibitors versus tamoxifen in early breast cancer : patient-level meta-analysis of the randomised trials

  2015cites this paper
• Breast cancer: Current and future endocrine therapies

  2014cites this paper
• Exercise intervention in breast cancer patients with aromatase inhibitor-associated arthralgia: a pilot study.

  2014cites this paper
• Aromatase inhibitors associated musculoskeletal disorders and bone fractures in postmenopausal breast cancer patients: a result from Chinese population

  2014cites this paper
• Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen.

  2014cites this paper
• Chapter 29 – Hormone Responsive Cancers

  2014cites this paper
• The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients

  2014cites this paper
• Adverse effects of endocrine therapy in breast cancer: single institute experience

  2014cites this paper
• NCCN Breast Cancer Version 3 . 2014 Clinical Practice Guidelines in Oncology

  2014cites this paper
• Women Commencing Anastrozole, Letrozole or Tamoxifen for Early Breast Cancer: The Impact of Comorbidity and Demographics on Initial Choice

  2014cites this paper
• Effects of tamoxifen and aromatase inhibitors on breast tissue enhancement in dynamic contrast-enhanced breast MR imaging: a longitudinal intraindividual cohort study.

  2014cites this paper
• Cardiotoxicity of systemic agents used in breast cancer.

  2014cites this paper
• Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up.

  2014cites this paper
• Breast cancer version 3.2014.

  2014cites this paper
• Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury.

  2014cites this paper
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines

  2014cites this paper
• Breast Cancer Genomics

  2014cites this paper
• Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian Tamoxifen Anastrozole trial.

  2013cites this paper
• Comparative efficacy study of 5-year letrozole or anastrozole in postmenopausal hormone receptor-positive early breast cancer.

  2013cites this paper